dc.contributor.author | Bamias, A. T. | en |
dc.contributor.author | Papamichael, D. | en |
dc.contributor.author | Syrigos, K. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Bamias, A. T. | en |
dc.creator | Papamichael, D. | en |
dc.creator | Syrigos, K. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:29Z | |
dc.date.available | 2018-06-22T09:52:29Z | |
dc.date.issued | 2003 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41379 | |
dc.description.abstract | The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/ mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil. Forty patients who had received 5-fluorouracil-based chemotherapy for advanced disease or adjuvant 5-fluorouracil treatment were enrolled. Chemotherapy consisted of irinotecan 125 mg/m2 and mitomycin C 5 mg/m2, given every 2 weeks. Treatment was continued until progression or limiting toxicity occurred. Five partial responses (12.5%), 22 cases of stable disease (55%) and 13 of progression (32.5%) were registered, giving an overall response rate of 12.5% [95% confidence interval (CI), 4.2-26.8%] and an overall control of tumor growth in 67.5% (95% CI, 50.8-81.4%) of patients. Median progression-free survival was 5 months, median survival time 8 months, and 1-year probability of survival was 21.6%. Diarrhea and neutropenia affected 25% and 12.5% of patients respectively, with only 7.5% experiencing grade 3-4 toxicity. There were no chemotherapy-related deaths or hospitalizations. This combination regimen was shown to be moderately effective with substantially lower toxicity than irinotecan monotherapy in 5-fluorouracil-pretreated patients with advanced gastric or colorectal cancer. It may represent an attractive option in patients at high risk for developing specific irinotecan toxicity. | en |
dc.language.iso | eng | en |
dc.source | Journal of Chemotherapy | en |
dc.subject | Article | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Drug response | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm staging | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Drug efficacy | en |
dc.subject | Monotherapy | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Salvage therapy | en |
dc.subject | Survival analysis | en |
dc.subject | Dexamethasone | en |
dc.subject | Drug administration schedule | en |
dc.subject | Drug fatality | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Treatment outcome | en |
dc.subject | Dose-response relationship | en |
dc.subject | Drug | en |
dc.subject | Colorectal cancer | en |
dc.subject | Epirubicin | en |
dc.subject | Folinic acid | en |
dc.subject | Disease course | en |
dc.subject | Male | en |
dc.subject | Sepsis | en |
dc.subject | Odds ratio | en |
dc.subject | Side effect | en |
dc.subject | Vomiting | en |
dc.subject | Follow-up studies | en |
dc.subject | High risk patient | en |
dc.subject | Stomach neoplasms | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Colorectal neoplasms | en |
dc.subject | Stomach cancer | en |
dc.subject | 4 dihydroxypyridine plus oxonate potassium plus tegafur | en |
dc.subject | 5 chloro 2 | en |
dc.subject | Acute cholinergic syndrome | en |
dc.subject | Advanced colorectal and gastric cancer | en |
dc.subject | Atropine | en |
dc.subject | Blood toxicity | en |
dc.subject | Bolus injection | en |
dc.subject | Camptothecin | en |
dc.subject | Chi-square distribution | en |
dc.subject | Cholinergic stimulation | en |
dc.subject | Combination chemotherapy | en |
dc.subject | Continuous infusion | en |
dc.subject | Drug tolerance | en |
dc.subject | Drug toxicity | en |
dc.subject | Hemolytic uremic syndrome | en |
dc.subject | Hospitalization | en |
dc.subject | Irinotecan | en |
dc.subject | Loperamide | en |
dc.subject | Maximum tolerated dose | en |
dc.subject | Mitomycin | en |
dc.subject | Mitomycin c | en |
dc.subject | Nausea | en |
dc.subject | Probability | en |
dc.subject | Risk assessment | en |
dc.subject | Second-line chemotherapy | en |
dc.subject | Survival time | en |
dc.subject | Third-line chemotherapy | en |
dc.subject | Toxicity | en |
dc.title | Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1179/joc.2003.15.3.275 | |
dc.description.volume | 15 | |
dc.description.issue | 3 | |
dc.description.startingpage | 275 | |
dc.description.endingpage | 281 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |